Eris Lifesciences Ltd.
NSE: ERISEris Lifesciences Ltd.: A 30-second snapshot
Eris Lifesciences (NSE: ERIS) is a mid-cap pharma company trading at ₹1,370.9, approximately 28% below its 52-week high and 10.4% below its 200-day SMA of ₹1,530.76. The trailing PE of 43.5 compresses to a forward PE of 27.3, reflecting analyst expectations of earnings growth, while a HALMED regulatory observation at its Swiss Parenterals subsidiary in April 2026 adds near-term operational uncertainty. Five-year earnings CAGR stands at 19.1% against revenue CAGR of 10.9%, with debt-to-equity of 68.2 on a rising trend.
P/E
43.5
Forward P/E
27.3
ROE
—
Debt / Equity
68.19
Profit Margin
+14.1%
Div. Yield
+1.0%
5Y ROE > 15%
3/5
5Y FCF > 0
3/5
Quality
47/100
News
8 headlines · 2 positive · 3 negative
Eris Lifesciences Receives HALMED Observations on Ahmedabad Units, Plans Corrective Actions - Medical Dialogues
Medical Dialogues
Eris Lifesciences drops after HALMED flags non-compliance issues at subsidiary units - Business Standard
Business Standard
HALMED Flags Non-Compliance at Swiss Parenterals; Eris Lifesciences Drops Nearly 6% - Trade Brains
Trade Brains
Eris says issues found at Swiss Parenterals units; impact likely minimal - CNBC TV18
CNBC TV18
Eris Lifesciences Limited Announces Postal Ballot for Appointment of Independent Director - scanx.trade
scanx.trade
Recent context
- ·HALMED flagged non-compliance at Swiss Parenterals' Ahmedabad units in April 2026; Eris management stated the impact is likely minimal and outlined corrective actions, though independent verification is pending.
- ·News sentiment across 8 headlines is split: 3 negative (regulatory), 3 neutral (governance, corporate actions), and 2 positive — overall classified as neutral, with the negative cluster concentrated around the HALMED event.
- ·A postal ballot was announced in April 2026 for the appointment of an independent director, indicating ongoing board-level governance activity.
Strengths
- +5-year earnings CAGR of 19.1% and revenue CAGR of 10.9% demonstrate consistent top- and bottom-line compounding over the medium term.
- +Forward PE of 27.3 represents a meaningful compression from the trailing PE of 43.5, indicating the market is pricing in earnings growth; this is below peers Apollo Hospitals (64.5) and Max Healthcare (72.4).
- +Dividend yield of 0.97% provides a modest income component alongside capital appreciation potential.
- +RSI of 51.5 in neutral territory and price above the 50-day SMA of ₹1,350.97 suggest short-term price stabilisation after the drawdown.
Weaknesses
- −Active HALMED regulatory observations at Swiss Parenterals subsidiary (April 2026) represent a material operational risk; non-compliance findings at manufacturing units can lead to import alerts, recall obligations, or remediation costs.
- −Debt-to-equity of 68.2 on a rising trend is elevated for a mid-cap pharma company; combined with FCF positive in only 3 of available years and consistency score of 41, balance-sheet durability is a concern.
- −Price is 10.4% below the 200-day SMA of ₹1,530.76 with a 28.2% drawdown from the 52-week high, reflecting sustained medium-term underperformance relative to the stock's own recent history.
- −Quality score of 43 ranks 4th of 6 in the sector peer set, trailing MAXHEALTH (54) and SUNPHARMA (50), indicating ERIS lags higher-quality peers on composite fundamentals.
Open questions
- ?How material is Swiss Parenterals to ERIS's total revenue and EBITDA, and what remediation timeline has management committed to for the HALMED observations?
- ?Does the 5-year earnings CAGR of 19.1% reflect recurring operating leverage in chronic-care segments, or is it partly attributable to acquisition-driven inorganic growth that may not repeat?
- ?Given a rising debt trend and D/E of 68.2, what is the company's FCF generation outlook relative to near-term debt maturities or capex commitments?
- ?The forward PE of 27.3 implies substantial earnings growth — what is the analyst consensus on FY26/FY27 earnings, and how has that estimate trended since the HALMED announcement?
Peer comparison: Pharma
Ranks 3 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ERIS | Eris Lifesciences Ltd.You're viewing | 43.5 | — | 43 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹1,370.90
SMA 50
₹1,350.97
SMA 200
₹1,530.76
RSI (14)
51.5 (neutral)
From 52w high
-28.2%
1Y return
-5.8%
3M return
-6.5%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highHALMED (Croatian Medicines and Medical Devices Agency) issued observations on non-compliance at Swiss Parenterals subsidiary units (Ahmedabad) in April 2026, causing a ~6% single-day price decline. Active regulatory action at a manufacturing subsidiary constitutes a material operational and reputational risk until corrective actions are independently verified.
- mediumDebt-to-equity of 68.2 is elevated relative to pharma peers and the debt trend is classified as rising. Quality score of 43 ranks 4th of 6 in the sector peer set, lagging MAXHEALTH (54) and SUNPHARMA (50). FCF was positive in only 3 of the available years with a consistency score of 41.
- mediumPrice of ₹1,370.9 is 10.4% below the 200-day SMA of ₹1,530.76 and 28.2% below the 52-week high. Stock has declined 5.8% over 12 months and 6.5% over 3 months, indicating sustained medium-term underperformance.
- lowROE is unavailable for ERIS, preventing direct comparison against sector peers (Cipla 11.74%, Dr. Reddy's 11.84%). Analyst consensus rating is also absent; only the count of 10 analysts is available, with no mean rating on record.
Cross-section contradictions
- Trailing PE of 43.5 is above peers Cipla (29.8) and Dr. Reddy's (26.7), yet forward PE compresses sharply to 27.3 — implying the market is pricing in substantial near-term earnings growth against a backdrop of active regulatory observations at a subsidiary.
- 5-year earnings CAGR of 19.1% and revenue CAGR of 10.9% reflect consistent compounding, yet the stock is 28.2% below its 52-week high with negative 1-year price change — growth track record and price action are diverging.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days